Synergistic inhibition of colorectal cancer progression by silencing Aurora A and the targeting protein for Xklp2

Figure 7 Knockdowns of Aurora A and targeting protein for Xklp2 inhibited epithelial-mesenchymal transition and knockdowns of Aurora A/targeting protein for Xklp2 pathways. A: Knockdowns of Aurora kinase A (AURKA)/targeting protein for Xklp2 (TPX2) or co-knockdown in SW480; B: AURKA/TPX2 knockdown or co-knockdown LOVO cells decreased N-cadherin, vimentin, AURKA, phosphorylated AURKA, and TPX2 expression, and increased E-cadherin expression. Epithelial-mesenchymal transition biomarkers include N-cadherin, E-cadherin, and vimentin. Western blotting was used to detect relative protein expression. ¹P < 0.05 vs negative control of short hairpin RNA (sh-NC) group. ²P < 0.01 vs sh-NC group. ³P < 0.05 vs short hairpin RNA of AURKA (sh-AURKA) group. ⁴P < 0.01 vs sh-AURKA group. ⁵P < 0.05 vs short hairpin-TPX2 (sh-TPX2) group. ⁶P < 0.01 vs sh-TPX2 group. AURKA: Aurora kinase A; TPX2: Targeting protein for Xklp2; sh-NC: Negative control of short hairpin RNA; sh-AURKA: Short hairpin RNA of Aurora kinase A; sh-TPX2: Short hairpin RNA of targeting protein for Xklp2; p-AURKA: Phosphorylated Aurora kinase A.